Market Overview

Why Coherus Biosciences 15% Dip Provides An Opportunity To Buy

Why Coherus Biosciences 15% Dip Provides An Opportunity To Buy
Related CHRS
Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut
51 Biggest Movers From Yesterday
Midday Gainers / Losers (07/18/2018) (Seeking Alpha)

Shares of Coherus Biosciences Inc (NASDAQ: CHRS) were trading down more than 15 percent on Monday following news that the Patent Trials and Appeals Board didn't institute their Intellectual Property Rights (IPR) '166 over Abbvie’s Humira.

Amid the price action, Citi analyst Mohit Bansal advised investors in a note that the institution of the ‘166 patent IPR isn't core to Citi’s thesis regarding Coherus and that investors should “buy on weakness.”

Bansal maintained a Buy rating and $36 price target for the stock.

"While this is being seen as a negative for CHRS, we note that our checks with patent experts did not suggest this patent was a key obstacle against a Humira biosimilar," said Bansal.

At time of writing, shares of Coherus were trading down around 11.5 percent at $24.90.

Latest Ratings for CHRS

May 2018Maxim GroupMaintainsBuyBuy
Mar 2018Maxim GroupMaintainsBuyBuy
Mar 2018CitigroupMaintainsBuyBuy

View More Analyst Ratings for CHRS
View the Latest Analyst Ratings

Posted-In: Citi Mohit BansalAnalyst Color Analyst Ratings Best of Benzinga


Related Articles (CHRS)

View Comments and Join the Discussion!